AstraZeneca Results Presentation Deck
BioPharmaceuticals: Cardiovascular, Renal & Metabolism
Total Revenue ($m)
Farxiga
41% growth at CER to $4,389m in 9M 2023
1,800
1,600
1,400
1,200
1,000
800
600
400
200
■EM
Q3
U
Q4 Q1 Q2
2021
Q3
2022
Q4
Q2
2023
441 498
578 579
72 138 136 105
393 456 506
296 339 366
320 318
391
63 78 99
423 410
98
84
EROW
■ Europe 213 225 318 309 329 342
202 228 193 275 279 323
US
Q1
Q3
Total Revenue ($m)
42 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World.
400
350
300
250
200
150
100
50
■ EM
0
EROW
■ Europe
■ US
Brilinta
Stable at CER at $996m in 9M 2023
Q3
Q4
2021
Q1
Q2
Q3 Q4
2022
Q1
76
71 69 78 76
64
82
16
16
14
14
10
8
6
85
83
76
73
65
67
67
198 178
166
185 187 206 179
Q2
2023
79
6
68
178
Q3
64
6
68
193
Total Revenue ($m)
120
100
80
60
40
20
☐EM
0
Lokelma
49% growth at CER to $300m in 9M 2023
EROW
■ Europe
■US
Q3
Q4
2021
1
13.
3
32
APPENDIX | 9M 2023 Product Performance
15
5
34
Q1
3
15
6
39
Q2
Q3 Q4
2022
2
18
7
39
9
17
8
45
6
18
9
48
Q1
11
20
11
56
Q2
2023
13
13.
22
24
14
16
49 51
Q3View entire presentation